Nicotine Replacement Therapies (NRTs): Uses, Benefits & Side Effects | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Nicotine Replacement Therapies (NRTs)
Therapeutic Class: Smoking Cessation Aid
Subclass: Nicotinic Receptor Agonist (Substitution Therapy)
Speciality: Psychiatry
Schedule (India):
- OTC: Nicotine gum ≤2 mg, Nicotine lozenges ≤2 mg
- Schedule H: Nicotine patches (all strengths), Nicotine gum/lozenges 4 mg
Route(s): Buccal (gum, lozenge), Transdermal (patch)
Formulations Available in India:
- Nicotine Chewing Gum: 2 mg, 4 mg
- Nicotine Lozenge: 2 mg, 4 mg
- Nicotine Transdermal Patch: 7 mg/24 hours, 14 mg/24 hours, 21 mg/24 hours
- Nicotine Nasal Spray: NOT AVAILABLE in India
- Nicotine Inhaler: NOT AVAILABLE in India
- Nicotine Mouth Spray: NOT AVAILABLE in India
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
▶ Tobacco Dependence — Smoking Cessation in Adults
Formulation Selection Guide:
| Cigarettes/Day | Fagerström Score | Recommended NRT |
| ≤10 | 0–3 (Low) | 2 mg gum/lozenge OR 14 mg patch |
| 11–20 | 4–6 (Moderate) | 4 mg gum/lozenge OR 21 mg patch |
| >20 | 7–10 (High) | 4 mg gum/lozenge + 21 mg patch (combination) |
A. Nicotine Chewing Gum
| Parameter | ≤20 cigarettes/day | >20 cigarettes/day |
|
Strength
|
2 mg | 4 mg |
|
Starting dose
|
1 piece every 1–2 hours | 1 piece every 1–2 hours |
|
Titration
|
Reduce frequency after 6 weeks | Reduce frequency after 6 weeks |
|
Usual maintenance dose
|
8–12 pieces/day | 8–12 pieces/day |
|
Maximum dose
|
24 pieces/day | 24 pieces/day |
Duration:
- Weeks 1–6: Regular use every 1–2 hours
- Weeks 7–9: One piece every 2–4 hours
- Weeks 10–12: One piece every 4–8 hours
- Total duration: 12 weeks (taper over last 2–4 weeks)
Technique (”Chew and Park“):
- Chew gum slowly until peppery/tingling taste appears
- Park between cheek and gum for 1 minute
- Resume chewing; repeat cycle for 30 minutes
- Discard after 30 minutes
B. Nicotine Lozenge
| Parameter | ≤20 cigarettes/day OR first cigarette >30 min after waking | >20 cigarettes/day OR first cigarette ≤30 min after waking |
|
Strength
|
2 mg | 4 mg |
|
Starting dose
|
1 lozenge every 1–2 hours | 1 lozenge every 1–2 hours |
|
Titration
|
Reduce frequency after 6 weeks | Reduce frequency after 6 weeks |
|
Usual maintenance dose
|
9–12 lozenges/day | 9–12 lozenges/day |
|
Maximum dose
|
15 lozenges/day | 15 lozenges/day |
Duration:
- Weeks 1–6: One lozenge every 1–2 hours (minimum 9/day)
- Weeks 7–9: One lozenge every 2–4 hours
- Weeks 10–12: One lozenge every 4–8 hours
- Total duration: 12 weeks
Technique:
- Allow lozenge to dissolve slowly in mouth (20–30 minutes)
- Move occasionally from side to side
- Do not chew or swallow whole
- Avoid eating/drinking 15 minutes before and during use
C. Nicotine Transdermal Patch
For Smokers >10 cigarettes/day:
| Phase | Duration | Patch Strength |
|
Step 1
|
Weeks 1–6 | 21 mg/24 hours |
|
Step 2
|
Weeks 7–8 | 14 mg/24 hours |
|
Step 3
|
Weeks 9–10 | 7 mg/24 hours |
For Smokers ≤10 cigarettes/day:
| Phase | Duration | Patch Strength |
|
Step 1
|
Weeks 1–6 | 14 mg/24 hours |
|
Step 2
|
Weeks 7–8 | 7 mg/24 hours |
Structured Summary:
| Parameter | Recommendation |
|
Starting dose
|
21 mg/24h (>10 cigs/day) OR 14 mg/24h (≤10 cigs/day) |
|
Titration
|
Step-down every 2–6 weeks as above |
|
Usual maintenance dose
|
As per step-down schedule |
|
Maximum dose
|
One 21 mg patch per 24 hours |
Application Instructions:
- Apply to clean, dry, hairless skin (upper arm, chest, hip)
- Rotate application site daily; do not reuse same site for 7 days
- Apply at same time each day (morning preferred)
- Remove at bedtime if sleep disturbance occurs (16-hour use option)
D. Combination NRT (Specialist Supervision)
For heavily dependent smokers (>20 cigarettes/day, Fagerström ≥7):
| Component | Dose | Role |
|
Patch
|
21 mg/24 hours | Baseline nicotine replacement |
|
Gum or Lozenge
|
2 mg or 4 mg as needed (max 5–6 pieces/day) | Breakthrough cravings |
Clinical Notes:
- More effective than monotherapy for highly dependent users
- Monitor closely for nicotine toxicity symptoms
- Reduce gum/lozenge use as cravings decrease
- Total duration: 12 weeks; may extend in specialist care
Secondary Indications — Adults (Off-label, if any)
| Indication | Dose | Duration | Notes |
|
Smokeless Tobacco Cessation (gutka, khaini, paan with tobacco)
|
2 mg or 4 mg gum/lozenge based on dependence level; standard schedule | 12 weeks | OFF-LABEL; Limited evidence; Behavioural support essential; Indian tobacco cessation clinic practice |
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Not applicable — NRT is NOT approved for use in patients below 18 years in India.
Secondary Indications — Paediatrics (Off-label, if any)
| Age Group | Indication | Dose | Duration | Notes |
|
16–17 years
|
Tobacco dependence (cigarette/smokeless) | 2 mg gum or lozenge every 2–4 hours OR 7–14 mg patch | ≤8 weeks | OFF-LABEL; Specialist only (Adolescent Medicine/Psychiatry); Must combine with behavioural counselling |
Safety Monitoring:
- Monitor for nicotine toxicity (nausea, headache, palpitations)
- Assess psychological dependence development
- Weekly follow-up during treatment
- Parental/guardian involvement essential
Age Restriction Statement:
- Not recommended below 16 years of age except under strict specialist supervision in tertiary centres
- No Indian paediatric data available
RENAL ADJUSTMENT
- No dose adjustment required for mild to moderate renal impairment
- End-stage renal disease (ESRD): Use with caution; nicotine metabolites may accumulate
- Haemodialysis: No specific recommendations; nicotine is dialysable but clinical significance unclear
HEPATIC ADJUSTMENT
| Severity | Recommendation |
|
Mild impairment
|
No dose adjustment required |
|
Moderate impairment
|
No specific adjustment; use standard doses with monitoring |
|
Severe impairment
|
Use with caution; nicotine clearance reduced by approximately 50%; consider lower doses or longer dosing intervals; specialist supervision advised |
CONTRAINDICATIONS
- Known hypersensitivity to nicotine or any formulation component (including adhesive in patches)
- Recent myocardial infarction (<2 weeks)
- Unstable or worsening angina pectoris
- Severe cardiac arrhythmias (e.g., uncontrolled ventricular tachycardia)
- Recent cerebrovascular accident (<2 weeks)
- Non-smokers or occasional smokers (risk of nicotine toxicity without tolerance)
CAUTIONS
- Stable cardiovascular disease: Benefit of cessation generally outweighs NRT risks; use with monitoring
- Uncontrolled hypertension: Monitor blood pressure
- Diabetes mellitus: Nicotine affects insulin sensitivity; monitor glucose closely
- Hyperthyroidism: Nicotine may exacerbate symptoms
- Phaeochromocytoma: Catecholamine release risk
- Peptic ulcer disease (active): Oral NRT may worsen symptoms
- Oesophagitis/pharyngitis: Oral NRT may cause irritation
- Dentures or temporomandibular joint disorders: Gum may be difficult to use
- Generalised skin disorders: Patch may cause irritation
- Concurrent smoking: Risk of nicotine overdose — emphasise complete abstinence from tobacco
- Seizure disorders: Use with caution
PREGNANCY
| Parameter | Recommendation |
|
Risk Category
|
Category D — Nicotine has known fetal risks; however, NRT is safer than continued smoking |
|
Safety Data
|
Nicotine associated with low birth weight, preterm birth; NRT delivers lower and more stable nicotine than smoking |
|
Preferred Alternatives
|
Behavioural counselling is first-line; non-pharmacological approaches preferred |
|
When May Be Used
|
If behavioural therapy fails and patient highly dependent; benefit of cessation outweighs NRT risk |
|
Formulation Preference
|
Short-acting (gum, lozenge) preferred over patch; if patch used, remove at bedtime (16-hour dosing) |
|
Monitoring
|
Fetal growth (serial ultrasound); maternal blood pressure; signs of nicotine toxicity |
LACTATION
| Parameter | Recommendation |
|
Compatibility
|
Compatible with breastfeeding; NRT preferred over continued smoking |
|
Formulation Preference
|
Short-acting (gum, lozenge) preferred; use immediately after feeding |
|
Expected Levels in Milk
|
Low to moderate; peak levels within 1 hour of use |
|
Timing
|
Avoid breastfeeding for 2–3 hours after gum/lozenge use |
|
Infant Monitoring
|
Irritability, poor feeding, sleep disturbance |
ELDERLY
| Parameter | Recommendation |
|
Starting Dose
|
Lower initial dose recommended — 2 mg gum/lozenge OR 14 mg patch |
|
Titration
|
Slower titration; assess response before increasing |
|
Extra Risks
|
Reduced nicotine clearance; cardiovascular effects more pronounced; dizziness and falls risk; denture-related gum difficulties |
|
Monitoring
|
Blood pressure; heart rate; symptoms of nicotine excess; gait and balance |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Adenosine
|
Nicotine increases heart rate; may counteract adenosine’s bradycardic effects | Larger adenosine dose may be required for cardiac stress testing |
Note on Smoking Cessation Effects (Not NRT-specific):
Smoking cessation (regardless of method) affects hepatic CYP1A2 enzyme activity. The following drugs may require dose adjustment upon quitting:
| Drug | Effect of Quitting | Management |
|
Theophylline
|
Levels increase (CYP1A2 substrate) | Reduce theophylline dose by 25–33%; monitor levels |
|
Clozapine
|
Levels increase significantly (CYP1A2 substrate) | Reduce dose by 30–50%; monitor closely; risk of toxicity |
|
Olanzapine
|
Levels may increase | Monitor; dose reduction may be needed |
|
Caffeine
|
Levels increase | Reduce caffeine intake to avoid toxicity symptoms |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Insulin
|
Smoking cessation may improve insulin sensitivity | Monitor blood glucose; reduce insulin dose as needed |
|
Oral hypoglycaemics
|
Similar effect as insulin | Monitor glycaemic control closely |
|
Warfarin
|
Smoking cessation may increase warfarin effect (CYP1A2) | Monitor INR closely; adjust dose as needed |
|
Beta-blockers
|
Nicotine may partially antagonise antihypertensive effect | Monitor blood pressure |
|
Alcohol
|
May worsen dizziness, nausea, flushing with NRT | Counsel on moderation |
COMMON ADVERSE EFFECTS
Nicotine Gum:
- Jaw pain/fatigue
- Hiccups
- Throat irritation
- Nausea
- Dyspepsia
- Altered taste
Nicotine Lozenge:
- Throat/mouth irritation
- Hiccups
- Heartburn
- Nausea
- Headache
- Cough
Nicotine Patch:
- Application site reactions (erythema, pruritus, burning)
- Insomnia
- Vivid/abnormal dreams
- Headache
- Dizziness
- Nausea
SERIOUS ADVERSE EFFECTS
- Nicotine overdose: Nausea, vomiting, abdominal pain, diarrhoea, sweating, pallor, headache, dizziness, tremor; severe cases — hypotension, bradycardia, seizures, respiratory depression — Requires immediate discontinuation and supportive care
- Acute coronary syndrome: Rare; in patients with unstable cardiovascular disease — Discontinue; emergency management
- Severe allergic reactions: Urticaria, angioedema (particularly with patch adhesive) — Discontinue immediately
- Seizures: Rare; in overdose or predisposed patients
MONITORING REQUIREMENTS
| Phase | Parameters |
|
Baseline
|
Smoking history (cigarettes/day, years); Fagerström Test for Nicotine Dependence (FTND) score; cardiovascular status (BP, HR); oral examination (for gum/lozenge users) |
|
After initiation (Weeks 1–4)
|
Abstinence status; craving control; dose adequacy; adverse effects (especially insomnia with patch, GI symptoms with oral NRT); continued tobacco use (toxicity risk) |
|
Long-term (>12 weeks)
|
Sustained abstinence; oral health (gum/lozenge users); skin integrity (patch users); cardiovascular parameters if comorbidities |
BRANDS AVAILABLE IN INDIA
Nicotine Gum:
- Nicotex® (Cipla)
- Nicogum® (Cipla)
- 2Baconil® (Rusan Pharma)
- Kwit®
- Nicotine Polacrilex (generic)
Nicotine Lozenge:
- Nicotex® Lozenge (Cipla)
- Smokinox® (Sun Pharma)
- 2Baconil® Lozenge
Nicotine Patch:
- Nicotex® Patch (Cipla)
- 2Baconil® TTS Patch (Rusan Pharma)
PRICE RANGE (INR)
| Formulation | Approximate Price |
| Nicotine Gum 2 mg (per piece) | ₹3–6 |
| Nicotine Gum 4 mg (per piece) | ₹5–8 |
| Nicotine Lozenge 2 mg (per piece) | ₹4–7 |
| Nicotine Lozenge 4 mg (per piece) | ₹6–10 |
| Nicotine Patch 7 mg/24h (per patch) | ₹40–60 |
| Nicotine Patch 14 mg/24h (per patch) | ₹50–80 |
| Nicotine Patch 21 mg/24h (per patch) | ₹70–100 |
- Not included in NLEM 2022
- Not under NPPA price control
- Widely available in retail pharmacies; limited in government sector
CLINICAL PEARLS
- Formulation choice matters: Patch provides steady nicotine levels (reduces baseline cravings); gum/lozenge allows flexible dosing for breakthrough cravings — combination is most effective for heavy smokers
- Technique is critical: Poor ”chew and park“ technique with gum results in swallowed nicotine, reduced efficacy, and increased GI side effects — patient education essential
- Sleep issues with patch: If insomnia or vivid dreams occur, remove patch at bedtime (16-hour use); efficacy is comparable
- NRT is safer than smoking: Even in stable cardiovascular disease, NRT risk is far lower than continued smoking — do not withhold NRT unnecessarily
- Oral NRT considerations: Avoid in active dental disease, oral mucositis, or recent oral surgery; acidic beverages (coffee, juice) reduce nicotine absorption — avoid 15 minutes before and during use
- Monitor for continued smoking: Patients using NRT while still smoking are at risk of nicotine toxicity — reinforce complete abstinence from tobacco products
TAGS
nicotine replacement therapy; NRT; nicotine gum; nicotine patch; nicotine lozenge; smoking cessation; tobacco dependence; OTC-partial; pregnancy-caution; cardiovascular-caution; elderly-caution
VERSION
RxIndia v0.2 — 03 Feb 2026
REFERENCES
- CDSCO approved formulations and product inserts
- Indian Pharmacopoeia / NFI 2021
- API Textbook of Medicine (Tobacco Use Disorders section)
- ICMR Guidelines on Tobacco Cessation
- National Tobacco Control Programme (NTCP) guidelines
- AIIMS Tobacco Cessation Clinic protocols
- WHO recommendations on tobacco cessation (supportive)
- Goodman & Gilman’s: The Pharmacological Basis of Therapeutics
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.